Explain alpha‑1 antitrypsin (AAT).

Alpha-1 Antitrypsin: Overview and Clinical Significance

Alpha-1 antitrypsin (AAT) is a 52-kD glycoprotein that functions primarily as a serine protease inhibitor, with its major biological role being the inhibition of neutrophil elastase to protect lung tissue from proteolytic destruction. 1

Basic Structure and Function

AAT is the most prevalent protease inhibitor in serum, normally circulating at concentrations of 120–200 mg/dL 1. The protein consists of:

• 394 amino acid residues with 3 asparagine-linked carbohydrate side chains
• An active site at the Met358-Ser359 peptide bond
• Gene location on chromosome 14q31-32.3, spanning 12.2 kb 1

Primary synthesis occurs in hepatocytes, though mononuclear phagocytes and intestinal/lung epithelial cells also produce AAT 1. The protein inhibits proteases by forming stable 1:1 equimolar complexes, with neutrophil elastase being its preferential target 1.

Beyond Protease Inhibition

Recent evidence demonstrates that AAT functions extend well beyond simple protease inhibition 2, 3. The protein exhibits:

• Anti-inflammatory properties through modulation of cytokine release
• Immunomodulatory effects on neutrophil recruitment
• Anti-apoptotic activities affecting cell survival pathways
• Regulation of oxidative stress mechanisms 2

AAT can bind to free fatty acids, inducing expression of angiopoietin-like protein 4, which is associated with dyslipidemia and inflammation 4. These broader functions suggest AAT's role in maintaining tissue homeostasis goes beyond the traditional protease-antiprotease paradigm 5.

Genetic Basis and Deficiency States

AAT deficiency is an autosomal codominant genetic disorder involving the protease inhibitor (PI) system 1. Approximately 100 alleles have been identified, with key variants including:

Common Phenotypes:

• PI*MM: Normal phenotype (most common)
• PI*ZZ: Most severe deficiency (~15% of normal levels, <50 mg/dL or <11 μM) 1
• PI*SZ: Intermediate deficiency
• PIMZ and PIMS: Heterozygous states with variable risk
• Null alleles (PI*QQ): Complete absence of active AAT 1

The protective serum threshold is 11 μM (approximately 35% of normal) 1. Levels below this threshold significantly increase risk for lung disease.

Clinical Manifestations

Pulmonary Disease

Panacinar emphysema, particularly affecting the lung bases, is the most prevalent clinical manifestation and the major cause of disability and death 1. The disease typically presents as:

• Early-onset COPD (often before age 45 in smokers)
• Basilar-predominant emphysema on imaging
• Progressive airflow obstruction
• Adult-onset asthma with persistent airflow limitation 6
• Unexplained bronchiectasis 6

Smoking dramatically accelerates disease progression, with PI*ZZ smokers developing symptoms 10-15 years earlier than non-smokers 1.

Liver Disease

Liver involvement results from intrahepatocytic accumulation of misfolded, polymerized AAT protein 1. This occurs specifically with the Z allele and certain other variants (S iiyama, M malton), but not with null variants or S allele 1.

Clinical patterns include:

• Neonatal cholestasis (common presentation in infancy, usually resolves)
• Cirrhosis affecting 30-40% of PI*ZZ individuals over age 50
• Hepatocellular carcinoma risk in older patients
• Peak cirrhosis incidence in elderly never-smokers who survived without severe emphysema 1

Male sex confers increased cirrhosis risk in PI*ZZ individuals 1.

Other Manifestations

Evidence supports associations with:

• Necrotizing panniculitis (rare)
• C-ANCA-positive vasculitis (anti-PR-3 positive) 1

Diagnostic Approach

The gold standard for diagnosis is serum phenotyping by isoelectric focusing performed by a reliable laboratory 1. However, the 2025 Canadian guidelines propose a more comprehensive approach:

Two-Step Diagnostic Algorithm 6, 7:

1. Initial screening: Measure serum AAT level

   • If <116 mg/dL (by immunonephelometry) with normal CRP → proceed to step 2

2. Confirmatory testing:

   • Targeted genotyping with PCR for common variants (Z, S)
   • DNA sequencing of SERPINA1 exons 2-5 represents the true gold standard, as it avoids misclassification from limited genotyping panels 6

Who to Test

Strong recommendations (Type A) for testing 1:

• All adults with COPD at time of diagnosis 6, 7
• Adults with adult-onset asthma and persistent airflow obstruction 6
• Individuals with unexplained bronchiectasis 6
• Unexplained liver disease (neonates, children, adults) 1
• Individuals with fixed airflow obstruction (FEV1/FVC <0.7 post-bronchodilator) 1
• Siblings of known homozygotes (25-100% chance of being affected) 1
• Individuals with occupational exposure to lung irritants 1

Type B recommendations (should be discussed):

• Adults with anti-PR-3-positive vasculitis 1
• Offspring or parents of homozygous individuals
• Partners of individuals with AAT deficiency for reproductive counseling 1

Type D recommendations (NOT recommended):

• Population screening of neonates, adolescents, or general adults 1
• Exception: May consider in countries with high prevalence (≥1/1,500), high smoking rates, and adequate counseling 1

Management Principles

General COPD Management

All patients require optimal standard COPD therapy regardless of AAT status 1, 6:

• Inhaled bronchodilators
• Influenza and pneumococcal vaccinations
• Supplemental oxygen when indicated
• Pulmonary rehabilitation for functional impairment
• Smoking cessation is absolutely critical (most important intervention)
• Early antibiotic therapy for purulent exacerbations (given increased elastolytic burden risk) 1

Augmentation Therapy

Intravenous AAT augmentation therapy is the only disease-modifying treatment approved for pulmonary disease 8. However, evidence quality remains limited.

Indications for augmentation therapy 7:

• Documented severe AATD with genotype associated with severe deficiency
• AAT levels <57.2 mg/dL (<11 μmol/L)
• Emphysema documented on CT
• Impaired pulmonary function
• Receiving optimal pharmacologic/nonpharmacologic treatment
• Not actively smoking

Important limitations:

• Augmentation therapy does NOT benefit liver disease 1
• Evidence is primarily observational (Grade II-2 to II-3) 1
• Cost is substantial and availability varies globally 8
• Duration of benefit and optimal dosing regimens remain under investigation 1

Liver Disease Management

No specific therapy exists for AAT-related liver disease except transplantation 1. Recommended surveillance includes:

• Hepatitis A and B vaccinations
• Regular physical examination and liver function tests
• Ultrasound examination
• For patients ≥50 years with decompensated cirrhosis: Periodic CT imaging for hepatocellular carcinoma screening (α-fetoprotein is insensitive) 1

Surgical Options

• Lung transplantation for severe functional impairment 1
• Lung volume reduction surgery: Possible benefit but shorter duration than in AAT-replete COPD; selection criteria remain unclear 1

Emerging Therapies

The therapeutic landscape is evolving rapidly 8:

• Inhaled AAT formulations (under investigation) 1
• Recombinant fusion proteins
• RNA-editing platforms
• CRISPR-based DNA editing strategies
• Chemical chaperones (e.g., 4-phenylbutyric acid) to correct protein misfolding and increase hepatocyte secretion 1

Critical Clinical Pitfalls

Delayed diagnosis remains the major problem, with patients diagnosed on average 5.3 years after first symptoms, often with FEV1 already at 52% predicted 6. This delay is associated with:

• Worse overall survival
• Worse transplant-free survival
• Reduced quality of life
• Irreversible lung damage

The clinical picture alone is inadequately sensitive to alert clinicians 6, emphasizing the need for systematic testing in at-risk populations rather than relying on clinical suspicion.

Common diagnostic errors:

• Assuming normal AAT levels in heterozygotes with active disease (isoelectric focusing required) 1
• Failing to test COPD patients systematically
• Misattributing symptoms to asthma or typical COPD
• Not recognizing basilar-predominant emphysema pattern on imaging